Over 175 biotechs adopt Veeva Basics to streamline drug development and regulatory processes

More than 175 emerging biotech companies are using Veeva Basics, a set of pre-configured applications, to streamline operations from clinical trials to regulatory submissions. This technology helps biotechs scale efficiently as they grow from startups to commercial stages, improving speed, compliance, and cost savings. Companies like Whitehawk Therapeutics and Structure Therapeutics highlight benefits such as replacing paper processes and insourcing regulatory publishing, leading to faster timelines and better quality control. Veeva Basics is built on the Vault Platform and supports biotech innovation by providing unified, scalable solutions for drug development and regulatory management.

Veeva Systems (VEEV) trades at USD 283.25 on Pluang as of Oct 07, 2026 18:22 WIB, showing a slight 0.11% decline in one day. The article highlights Veeva Basics' role in helping over 175 emerging biotech companies streamline drug development and regulatory processes. Despite the small dip, VEEV maintains a strong market cap of $45.90 billion and a 52-week high of $306.22, indicating sustained investor interest in its technology solutions.